Liver cancer is a global burden:¹

- The 6th most common cancer²
- The 3rd most common cause of cancer deaths³

The leading cause of death in people with cirrhosis³

ASR (World) per 100,000⁰:
- ≥ 8.9
- 6.1–8.9
- 4.8–6.1
- 3.7–4.8
- < 3.7
- Not applicable
- No data

Most liver cancer is caused by viral hepatitis:³

- 54% HCV
- 31% HBV
- 15% Alcohol, fatty liver and other

There are substantial regional variations. Fatty liver disease will be increasingly important as it becomes more common⁴

For more information and to learn what EASL is doing to combat liver cancer, visit the EASL website and social media pages

Types of primary liver cancer

- Hepatocellular carcinoma (HCC):³
  - The most common liver cancer, accounting for ~90% of all liver cancers. It forms in hepatocytes, which make up the majority of liver cells
- Intrahepatic cholangiocarcinoma:⁵
  - The second most common liver cancer (10–15% of cases), which begins in the cells that line the small bile ducts within the liver
- Hemangioendothelioma and hepatic angiosarcoma:⁶,⁷
  - A rare malignant cancer that begins in cells lining blood vessels within the liver
- Hepatoblastoma:⁸
  - A rare cancer that typically develops in children <5 years of age

RISK FACTORS

- Hepatitis B³
- Hepatitis C³
- Fatty liver disease³
- Alcohol consumption³
- Metabolic diseases³
- Environmental toxins³
- Bile duct disease³
- Genetic haemochromatosis³

PREVENTION:³

- Reduce alcohol intake
- Vaccinate against hepatitis B
- Detect and treat chronic hepatitis
- Healthy lifestyle to reduce obesity

CIRRHOSIS AND HCC:³

- 1/3 of people with liver cirrhosis will develop HCC per year
- 1–8% of people with cirrhosis develop HCC per year
- 90% of HCC cases in Western countries have a cirrhotic background

TREATMENT OPTIONS:³,⁹

- Resection
- Liver transplantation
- Local ablation
- Loco-regional therapy
- Systemic treatments and immunotherapy

Screening, raising awareness of risk factors and lifestyle changes can help minimize cancer-related and overall liver-related deaths

LIVER CANCER EXPLAINED

For more information and to learn what EASL is doing to combat liver cancer, visit the EASL website and social media pages

³ EASL. J Hepatol 2018;69:182–236
⁵ Asrani SK, et al. J Hepatol 2019;70:151–171
⁸ Calvisi DF and Solinas A. Transl Gastroenterol Hepatol 2020; doi: 10.21037/tgh.2019.12.03

*Age-standardized incidence rate per 100,000 people. This is the weighted average of the age-specific incidence rates per 100,000 persons, where the weights are the proportions of people in different age groups of the standard population.